earnings
confidence high
sentiment neutral
materiality 0.75
OptimizeRx Q2 revenue $18.8M (+36% YoY); GAAP EPS loss $(0.22); guides FY rev >=$100M
OptimizeRx Corp
2024-Q2 EPS reported
-$0.60
revenue$38,502,000
- Revenue $18.8M (+36% YoY); gross profit $11.7M (+50%); gross margin 62%.
- GAAP net loss $(4.0M) ($(0.22)/share); non-GAAP net income $0.3M ($0.02/diluted).
- Adjusted EBITDA $0.5M vs $(0.8M) prior year; FY2024 guidance reaffirmed: rev >=$100M, Adj EBITDA >=$11M.
- CEO cites ~$6M DAAP program delayed from Q2; without delay would have exceeded consensus.
- KPIs: avg rev per top 20 pharma $2.7M (up from $1.8M); net revenue retention 124% (vs 89%).